Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 246-251

  Costet, P ^a,b   Hoffmann, M M ^c   Cariou, B ^a,b,d   Delasalle, B Guyomarc'h ^a   Konrad, T ^e   Winkler, K ^c  

^a INSERM   (France)

^b L INSTITUT DU THORAX   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITÉ DE NANTES   (France)

^e Institute for Metabolic Research   (Germany)

Author keywords

Diabetes; Fenofibrate; HDL; LDL; PCSK9; Statin; Triglyceride

Indexed keywords

ATORVASTATIN; FENOFIBRATE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FRANCE; GERMANY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PYRROLES; SERINE ENDOPEPTIDASES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UP-REGULATION;

EID: 77956230636     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.05.027     Document Type: Article

References (29)

1. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
2. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005, 96:556-563.
3. Rosenson R.S. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008, 6:1319-1330.
4. Tikkanen M.J., Holme I., Cater N.B., et al. Comparison of efficacy and safety of atorvastatin (80mg) to simvastatin (20 to 40mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol 2009, 103:577-582.
5. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
6. Costet P., Krempf M., Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 2008, 33:426-434.
7. Zhang D.W., Lagace T.A., Garuti R., et al. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282:18602-18612.
8. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
9. Cariou B., Ouguerram K., Zair Y., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29:2191-2197.
10. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J Biol Chem 2006, 281:6211-6218.
11. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
12. Jeong H.J., Lee H.S., Kim K.S., Kim Y.K., Yoon D., Park S.W. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol regulatory element-binding protein-2. J Lipid Res 2007, 49:399-409.
13. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49:394-398.
14. Dubuc G., Tremblay M., Pare G., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
15. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
16. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26:1094-1100.
17. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005, 102:5374-5379.
18. Zaid A., Roubtsova A., Essalmani R., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48:646-654.
19. Kourimate S., Le M.C., Langhi C., et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008, 283:9666-9673.
20. Lambert G., Jarnoux A.L., Pineau T., et al. Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology 2006, 147:4985-4995.
21. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels. J Lipid Res 2009, 51:345-351.
22. Mayne J., Dewpura T., Raymond A., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008, 7:22.
23. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by Fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
24. Kourimate S., Chetiveaux M., Jarnoux A.L., Lalanne F., Costet P. Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes. Atherosclerosis 2009, 206:134-140.
25. Li H., Dong B., Park S.W., Lee H.S., Chen W., Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009, 284:28885-28895.
26. Dong B., Wu M., Li H., et al. Strong induction of PCSK9 gene expression through HNF1{alpha} and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 2010.
27. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 1998, 53:14-22.
28. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009, 106:9820-9825.
29. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010.